These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1696 related articles for article (PubMed ID: 31647985)

  • 1. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
    Brett JO; Spring LM; Bardia A; Wander SA
    Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
    Jeselsohn R; De Angelis C; Brown M; Schiff R
    Curr Oncol Rep; 2017 May; 19(5):35. PubMed ID: 28374222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
    Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
    J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
    Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
    Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
    Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
    JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
    Linden HM; Kurland BF; Peterson LM; Schubert EK; Gralow JR; Specht JM; Ellis GK; Lawton TJ; Livingston RB; Petra PH; Link JM; Krohn KA; Mankoff DA
    Clin Cancer Res; 2011 Jul; 17(14):4799-805. PubMed ID: 21750198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of SERENA-6, a phase III switching trial of camizestrant in
    Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC
    Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-positive (ER
    Ferreira Almeida C; Oliveira A; João Ramos M; Fernandes PA; Teixeira N; Amaral C
    Biochem Pharmacol; 2020 Jul; 177():113989. PubMed ID: 32330493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
    Wang Y; Tang SC
    Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.
    Liang J; Ingalla ER; Yao X; Wang BE; Tai L; Giltnane J; Liang Y; Daemen A; Moore HM; Aimi J; Chang CW; Gates MR; Eng-Wong J; Tam L; Bacarro N; Roose-Girma M; Bellet M; Hafner M; Metcalfe C
    Sci Transl Med; 2022 Sep; 14(663):eabo5959. PubMed ID: 36130016
    [No Abstract]   [Full Text] [Related]  

  • 16. ESR1 mutations in breast cancer.
    Dustin D; Gu G; Fuqua SAW
    Cancer; 2019 Nov; 125(21):3714-3728. PubMed ID: 31318440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.
    Keenan JC; Medford AJ; Dai CS; Wander SA; Spring LM; Bardia A
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):397-405. PubMed ID: 38642015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
    Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
    Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor mutations and their role in breast cancer progression.
    Alluri PG; Speers C; Chinnaiyan AM
    Breast Cancer Res; 2014 Dec; 16(6):494. PubMed ID: 25928204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.